Namely, in imatinib-treated CML patients, there is an upregulation of interferon γ (IFNγ) production by activated T cells, which leads to the inhibition of the constitutive STAT5 activation. The gene discussed is IFNG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.